INVIVYD, INC. Interest Income (Expense), Nonoperating, Net
INVIVYD, INC. (IVVD) reported Interest Income (Expense), Nonoperating, Net of $1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-13
- INVIVYD, INC. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $1.50M, a 271.11% increase year-over-year.
- INVIVYD, INC. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $1.52M, a 70.59% increase year-over-year.
- INVIVYD, INC. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $554.00K, a 64.56% decline year-over-year.
- INVIVYD, INC. interest income (expense), nonoperating, net for the quarter ending 2025-06-30 was $405.00K, a 81.28% decline year-over-year.
- INVIVYD, INC. interest income (expense), nonoperating, net for fiscal 2025 was $3.11M, a 56.94% decline from fiscal 2024.
- INVIVYD, INC. interest income (expense), nonoperating, net for fiscal 2024 was $7.22M, a 49.05% decline from fiscal 2023.
- INVIVYD, INC. interest income (expense), nonoperating, net for fiscal 2023 was $14.16M.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-08-13 | $3.25M 10-Q · filed 2026-08-13 | ||
| 2025-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.07M derived: sum of 2 quarters · filed 2026-03-05 | $2.48M derived: sum of 3 quarters · filed 2026-08-13 | $3.11M 10-K · filed 2026-03-05 |
| 2025-09-30 | $554.00K 10-Q · filed 2025-11-06 | $959.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.59M 10-Q · filed 2025-11-06 | $2.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $405.00K 10-Q · filed 2026-08-13 | $1.03M 10-Q · filed 2026-08-13 | $1.92M derived: sum of 3 quarters · filed 2026-08-13 | $3.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $628.00K 10-Q · filed 2025-05-15 | $1.52M derived: sum of 2 quarters · filed 2026-03-05 | $3.08M derived: sum of 3 quarters · filed 2026-03-05 | $5.25M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | $891.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.45M derived: sum of 2 quarters · filed 2026-03-05 | $4.62M derived: sum of 3 quarters · filed 2026-03-05 | $7.22M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.56M 10-Q · filed 2025-11-06 | $3.73M derived: sum of 2 quarters · filed 2025-11-06 | $6.33M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.16M 10-Q · filed 2025-08-14 | $4.76M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $2.60M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $14.16M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |